Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V116 in Children and Adolescents at Risk for Pneumococcal Disease
NCT06177912Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 13
01
Overview
A Phase 3 trial of pneumococcal 21-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jan 2024; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06177912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177912.